Subscribe to Search results

Dr Jones noted that cryoprecipitate was the treatment of choice for haemophiliacs, but when not available FFP would be used.

Published on:

Dr Jones championed the use of cryoprecipitate in haemophiliacs as early as 1972, as per his article "Answering the needs of haemophilic children and their families Community Medicine"

Published on:

It was noted in a report on the optimum use of Factor VIII preparations that at the Newcastle Haemophilia Centre cryoprecipitate would be used to treat bleeds in most circumstances and it was also used for surgery and dental extraction, whilst Hemofil was used for home therapy and for severe bleeds.

Published on:

Dr Jones stated in a publication 'AIDS and the Blood' that it was best practice to treat children under 4 with cryoprecipitate.

Published on:

Dr Jones in his statement to the Inquiry could not explain the discrepancy in the age range for cryoprecipitate but it was trying to cover the youngest children.

Published on:

Dr Jones stated that if NHS concentrates had been manufactured to the same general standards of the commercial concentrates, they would have been used exclusively for home therapy in the UK.

Published on:

Dr Jones stated that clinicians were only reliant on commercial concentrates because there was insufficient NHS product.

Published on:

Dr Jones in his statement to the Inquiry noted that he increased testing and surveillance at the Newcastle Centre when the risk of AIDS for people with haemophilia was brought to his attention.

Published on:

Dr Hamilton, on behalf of Dr Jones attended a meeting at a Heathrow Airport hotel where AIDS was discussed, however Dr Jones does not recall discussing the meeting or taking specific action as a result of this meeting.

Published on:

Dr Jones decided that despite some risk regarding Factor concentrate at the time, the switch to cryoprecipitate was not made.

Published on:

Dr Jones noted that in response to the risk of AIDS in the early 80's, the Newcastle Centre took the following action: cryoprecipitate was reserved for children, factor concentrates continued to be used and non urgent surgery was put off.

Published on:

Dr Jones explained at the 3rd European Regional Congress of the Federation of Haemophilia in London that his policy was to treat under 6s with domestic cryoprecipitate while those above were treated with factor concentrates.

Published on:

By 1975, the use of commercial concentrate in the Northern Region had rapidly increased to 972,000 units; and by 1976, a great deal more commercial concentrate (1,649,240 units) was used than cryoprecipitate (676,050 units) and NHS concentrate (82,800 units) put together.

Published on:

The Newcastle Haemophilia Centre annual returns from 1976 to 1979 recorded that Hemofil was the main product used for the treatment of Haemophilia A

Published on:

The 1977 Newcastle Haemophilia Centre annual return recorded a very substantial increase in the use of Hemofil (2.3 million units, compared to 1.6 million units of NHS product).

Published on:

The annual retruns for Newcastle Haemophilia Centre recorded that 1978 Hemofil, Factorate and Koate were all in use, along with NHS concentrate.

Published on:

The individual records enclosed with the 1979 return for the Newcastle Haemophilia Centre demonstrated that a number of individuals were treated with multiple products rather than kept on a single product.

Published on:

It was reported that at the Newcasle Haemophilia centre approximately 180,000 units of commercial concentrate had been bought in the past year to make up "the deficit in BTS supplied VIII products for in-patient use" within the Northern Regional Haemophilia Service.

Published on:

It was clear, from a letter written by Dr Jones, that commercial concentrates were considered to be preferable for home therapy for reasons including "size of bottle, volume of fluid required for reconstitution, time of reconstitution, viscosity".

Published on:

In her statement, Anne Kirkman Collins stated that the Newcastle Haemophilia Centre preferred commercial Factor VIII product because: it was more easily soluble, some patients had allergic reactions to NHS Factor VIII and the presentation of commercial product was more appealing to the centre.

Published on: